

Bioinorganic Medicinal Chemistry

Edited by
Enzo Alessio



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

Contents

List of Contributors XV

1	Medicinal Inorganic Chemistry: State of the Art, New Trends, and a Vision of the Future	1
	<i>Nicola J. Farrer and Peter J. Sadler</i>	
1.1	Introduction	1
1.1.1	Metals in the Body: Essential Elements and Diseases of Metabolism	6
1.1.2	Metals as Therapeutic Agents	6
1.2	Antimicrobial Agents	8
1.3	Antiviral Agents	15
1.4	Systemic and Metabolic Diseases Including Inflammation	18
1.4.1	Diabetes and Obesity	18
1.4.2	Metal Homeostasis and Related Diseases	19
1.5	Metal Chelating Agents	19
1.6	Antiarthritic Drugs and Inflammation	21
1.7	Bipolar Disorder	22
1.8	Anticancer Agents	22
1.8.1	Pt ^{II} Cytotoxic Agents	23
1.8.2	Pt ^{IV} Prodrugs	24
1.8.3	Photoactivatable Pt ^{IV} Complexes	25
1.8.4	Ruthenium	25
1.8.4.1	Interaction with Plasma Proteins	25
1.8.4.2	Ruthenium Arenes	26
1.8.5	Osmium	29
1.8.6	Titanium	29
1.8.7	Gold	31
1.8.8	Tin	32
1.8.9	Gallium	33

1.8.10	Arsenic	33
1.8.11	Copper	34
1.8.12	Zinc	34
1.8.13	Bismuth	34
1.8.14	Molybdenum	35
1.8.15	Photosensitizers: Porphyrins	35
1.9	Small Molecule Delivery and Control	35
1.9.1	Nitric Oxide (NO)	35
1.9.2	Carbon Monoxide (CO)	36
1.10	Diagnostic Agents	36
1.11	Veterinary Medicinal Inorganic Chemistry	37
1.12	Conclusions and Vision	37
2	Targeting Strategies for Metal-Based Therapeutics	49
	<i>Julia F. Norman and Trevor W. Hambley</i>	
2.1	Introduction	49
2.2	Physiological Targeting	49
2.2.1	Antitumor Drugs Targeting Tumor Hypoxia	50
2.2.2	Antitumor Drugs Targeting Vascular Structure	54
2.2.3	Antitumor Drugs Targeting Tumor pH	54
2.2.4	Light Activated Prodrugs	55
2.3	Molecular Targeting	57
2.3.1	Protein and Peptide Targeting	57
2.3.1.1	Protein Receptor Binding	57
2.3.2	Peptide Tethering	63
2.3.2.1	Directing Effects	64
2.3.3	Selective Activation	65
2.3.4	DNA Targeting	66
2.3.4.1	Duplex DNA Sequence Selectivity	66
2.3.4.2	Telomeric Targeting	68
2.4	Immunological Targeting	69
2.4.1	Antigen Targeting	70
2.4.2	Antibody Tethering	71
2.5	Concluding Remarks	73
3	Current Status and Mechanism of Action of Platinum-Based Anticancer Drugs	79
	<i>Shanta Dhar and Stephen J. Lippard</i>	
3.1	Introduction	79
3.1.1	Platinum Chemotherapy and Cancer	79
3.1.2	Palette of Current Platinum Chemotherapeutic Drugs	79
3.1.3	Early History of Cisplatin and Approved Platinum Drugs for the Clinic	82
3.2	Mechanism of Action of Cisplatin	82
3.2.1	Cisplatin Accumulation	82
3.2.2	Cisplatin Activation	82

3.2.2.1	Binding to DNA Targets	83
3.2.2.2	Binding to Non-DNA Targets	84
3.2.3	Cellular Processing of Platinum-DNA Adducts	84
3.2.3.1	Cytotoxicity Associated with High Mobility Group (HMG) Proteins	85
3.2.3.2	Cytotoxicity Associated with Non-HMG Proteins	86
3.3	Limitations of Current Platinum-Based Compounds: New Strategies	87
3.4	Novel Concepts in the Development of Platinum Antitumor Drugs	87
3.4.1	Functionalized Single-Walled Carbon Nanotubes (SWNTs) as Vehicles for Delivery of Pt(IV)-Prodrugs	88
3.4.2	Targeted Nanoparticles for Delivery of Cisplatin for Prostate Cancer	89
3.4.3	Gold Nanoparticles as Delivery Vehicles for Platinum Compounds	90
3.4.4	Delivery of Pt(IV) Compounds Targeting Cancer Cell Metabolism	91
3.5	Concluding Remarks	93
4	New Trends and Future Developments of Platinum-Based Antitumor Drugs	97
	<i>Xiaoyong Wang and Zijian Guo</i>	
4.1	Introduction	97
4.2	Mechanisms of Action and Resistance	99
4.2.1	Mechanism of Action	99
4.2.2	Mechanism of Resistance	100
4.2.2.1	Decreased Drug Accumulation	100
4.2.2.2	Increased Detoxification	101
4.2.2.3	Enhanced Repair and Increased Tolerance to DNA Damage	101
4.2.2.4	Reduced Apoptotic Response and Activation of Survival Pathways	102
4.3	Monofunctional Platinum(II) Complexes	103
4.4	Trans-Platinum(II) Complexes	107
4.5	Multinuclear Platinum(II) Complexes	114
4.6	Platinum(IV) Complexes	124
4.7	Delivery of Platinum Drugs	130
4.8	Concluding Remarks and Future Perspectives	139
5	Ruthenium and Other Non-platinum Anticancer Compounds	151
	<i>Ioannis Bratsos, Teresa Gianferrara, Enzo Alessio, Christian G. Hartinger, Michael A. Jakupec, and Bernhard K. Keppler</i>	
5.1	Introduction	151
5.2	Ruthenium Anticancer Compounds	152

- 5.2.1 Chemical Features of Ruthenium Compounds 152
- 5.2.2 *Trans*-[tetrachloridobis(1*H*-indazole)ruthenate(III)] Complexes and their Development 153
- 5.2.3 Ruthenium-dmso Compounds: The Development of NAMI-A 156
 - 5.2.3.1 Chemical Features of NAMI-A 157
 - 5.2.3.2 NAMI-A-Type Complexes 158
 - 5.2.3.3 Mechanism of Action of NAMI-A 159
- 5.2.4 Half-Sandwich Ru-Organometallics 160
 - 5.2.4.1 Piano-Stool Ru-Arene Compounds 160
 - 5.2.4.2 RAPTA Compounds 162
 - 5.2.4.3 Other Half-Sandwich Ru Compounds 163
- 5.3 From Gallium Nitrate to Oral Gallium Complexes 164
- 5.4 Titanium Anticancer Compounds 165
 - 5.4.1 Budotitane: The First Transition Metal Complex in Clinical Trials in the Post-cisplatin Era 165
 - 5.4.2 Titanocene Dichloride and Related Compounds 166
- 5.5 Ferrocene-Derived Anticancer Agents 166
- 5.6 The Main Group Organometallics Spirogermanium and Germanium-132 167
- 5.7 Arsenic in Cancer Chemotherapy 168
- 5.8 Overcoming the Resistance of Tumors to Anticancer Agents by Rare Earth Element Compounds 169
- 5.9 Conclusions 170

- 6 The Challenge of Establishing Reliable Screening Tests for Selecting Anticancer Metal Compounds 175**
Angela Boccarelli, Alessandra Pannunzio, and Mauro Coluccia
- 6.1 Introduction 175
- 6.2 Tumor Cell Growth Inhibition and Cell Death Screening Assays 177
- 6.3 Metal-Based Anticancer Compounds and Gene Expression Microarray Technologies 181
 - 6.3.1 Basal Transcription Profiling and Sensitivity/Resistance to Metal-Based Anticancer Drugs 183
 - 6.3.2 Profiling Gene Expression Alterations in Response to Treatment with Metal-Based Anticancer Drugs 185
- 6.4 Metal-Based Anticancer Compounds and the Proteomic Approach 187
- 6.5 Concluding Remarks 190
 - 6.5.1 Cytotoxic Metal-Based Anticancer Agents 190
 - 6.5.2 Non-Cytotoxic Metal-Based Anticancer Agents 190
 - 6.5.3 Tumor-Targeted Metal-Based Anticancer Agents 191
 - 6.5.4 Towards a Global Mechanistic-Based Screening Approach 191

7	Gold-Based Therapeutic Agents: A New Perspective	197
	<i>Susan J. Berners-Price</i>	
7.1	Introduction	197
7.1.1	An Historical Perspective	197
7.1.2	Current Interest in Gold-Based Drugs	199
7.2	Biological Chemistry of Gold	200
7.2.1	Gold(I) Oxidation State	200
7.2.2	Gold(III) Oxidation State	202
7.3	Gold Antiarthritic Drugs	202
7.3.1	Structural Chemistry and Biotransformation Reactions	202
7.3.2	Mode of Action	204
7.4	Gold Complexes as Anticancer Agents	205
7.4.1	Gold(I) Compounds	205
7.4.1.1	Auranofin and Related Compounds	205
7.4.1.2	Tetrahedral Gold(I) Diphosphines and Related Compounds	206
7.4.1.3	Gold(I) N-Heterocyclic Carbene Compounds	209
7.4.2	Gold (III) Compounds	210
7.4.3	Mode of Action of Gold-Based Anticancer Drugs	212
7.5	Gold Complexes as Antiparasitic Agents	214
7.6	Concluding Remarks	215
8	MRI Contrast Agents: State of the Art and New Trends	223
	<i>Daniela Delli Castelli, Eliana Gianolio, and Silvio Aime</i>	
8.1	Introduction	223
8.2	T ₁ Agents	224
8.2.1	Theory of Paramagnetic Relaxation	224
8.2.2	Clinically Approved T ₁ Agents	227
8.2.2.1	Paramagnetic Gd(III)-Based Complexes	227
8.2.2.2	Mn(II)-Based Complexes	229
8.2.3	Preclinical Level	230
8.2.3.1	ECF Agents	230
8.2.3.2	Blood Pool Agents	231
8.2.3.3	Responsive T ₁ Agents	232
8.3	T ₂ -Susceptibility Agents	234
8.3.1	Iron Oxide Particles	235
8.3.2	Paramagnetic Liposomes	235
8.4	CEST Agents	236
8.4.1	Theoretical Background	237
8.4.1.1	The Sensitivity Issue	239
8.4.2	Paramagnetic CEST Agents: PARACEST	241
8.4.2.1	Responsive PARACEST Agents	244
8.4.2.2	Cell Labeling	248
8.5	Concluding Remarks	249

9	Metal-Based Radiopharmaceuticals	253
	<i>Roger Alberto</i>	
9.1	Introduction	253
9.1.1	Selection of the Radionuclide	254
9.1.2	Production of Radionuclides	255
9.1.3	Concepts and Chemistry of Labeling	258
9.1.4	Different Generations of Metal-Based Radiopharmaceuticals	260
9.2	Selected Examples: Therapeutic Radiopharmaceuticals	262
9.2.1	The “3 + Family”: Yttrium and Some Lanthanides	262
9.2.2	Rhenium	265
9.2.3	α -Emitters: Bismuth and Actinium	267
9.3	Diagnostic Metal-Based Radiopharmaceuticals	269
9.3.1	The “3 + Family Continued”: Indium and Gallium	269
9.3.2	Technetium	272
9.3.3	Targeted Radiopharmaceuticals: Technetium-Labeled Carbohydrates	274
9.3.4	Technetium-Essential Radiopharmaceuticals for Heart Imaging	276
9.4	Perspectives and Conclusion	278
10	Boron and Gadolinium in the Neutron Capture Therapy of Cancer	283
	<i>Ellen L. Crossley, H. Y. Vincent Ching, Joseph A. Ioppolo, and Louis M. Rendina</i>	
10.1	Introduction	283
10.2	Boron Neutron Capture Therapy	284
10.2.1	Key Criteria for BNCT Agents	285
10.2.2	Clinical BNCT Agents	286
10.3	Role of Medicinal Inorganic Chemistry in BNCT	287
10.3.1	Platinum–Boron Agents	288
10.3.2	Boronated Porphyrins	289
10.3.3	Boronated Phosphonium Salts	290
10.3.4	Radiolabeling of Boronated Agents for <i>In Vivo</i> Imaging	291
10.3.5	Radiofluorination of BPA	292
10.3.6	Carborane Radiohalogenation	292
10.3.7	Radiometallacarboranes	293
10.4	Gadolinium Neutron Capture Therapy	294
10.4.1	Archetypal Gd NCT Agents	295
10.4.2	Hybrid Boron–Gadolinium Agents	296
10.5	Conclusions and Future Outlook	297

11	Essential Metal Related Metabolic Disorders	307
	<i>Yasmin Mawani and Chris Orvig</i>	
11.1	Introduction: What is Essentiality?	307
11.2	Iron Metabolic Diseases: Acquired and Genetic	307
11.2.1	Iron Homeostasis	307
11.2.2	Diseases of Primary Iron Overload: Hemochromatosis	309
11.2.2.1	Type 1 Hereditary Hemochromatosis	309
11.2.2.2	Type 2 Hereditary Hemochromatosis: Juvenile Hemochromatosis	309
11.2.2.3	Type 3 Hereditary Hemochromatosis	311
11.2.2.4	Type 4 Hereditary Hemochromatosis: African Iron Overload	311
11.2.2.5	Neonatal Hemochromatosis	311
11.2.3	Diseases of Iron Overload: Accumulation of Iron in the Brain	311
11.2.3.1	Aceruloplasminemia	312
11.2.3.2	Hallervorden–Spatz Syndrome (HSS)	312
11.2.3.3	Friedreich’s Ataxia	312
11.2.4	Acquired Iron Overload Disorders	313
11.2.5	Treatment of Iron Overload Disorders: Chelation Therapy	313
11.2.6	Iron Deficiency	314
11.3	Copper Metabolic Diseases	315
11.3.1	Copper Homeostasis	315
11.3.2	Copper Deficiency: Menkes Disease	317
11.3.3	Copper Overload: Wilson’s Disease	318
11.3.4	Treatment of Wilson’s Disease: Chelation Therapy	318
11.4	Zinc Metabolic Diseases	319
11.4.1	Zinc Homeostasis	319
11.4.2	Zinc Overload: Zinc Toxicity	321
11.4.3	Treatment of Zinc Toxicity: Chelation Therapy	321
11.4.4	Acquired Zinc Deficiency	322
11.4.5	Genetic Zinc Deficiency: Acrodermatitis Enteropathica	322
11.5	Diseases Related to Imbalances in Electrolytic Metabolism: P, the Alkali Metals, and the Alkaline Earths	323
11.5.1	Sodium	324
11.5.1.1	Hyponatremia	326
11.5.1.2	Hypernatremia	327
11.5.2	Magnesium	328
11.5.2.1	Hypomagnesemia	328
11.5.2.2	Hypermagnesemia	329
11.5.3	Potassium	330
11.5.3.1	Hypokalemia	330
11.5.3.2	Hyperkalemia	331
11.5.4	Phosphorus	332
11.5.4.1	Hypophosphatemia	333

- 11.5.4.2 Hypophosphatasia 334
- 11.5.4.3 Hyperphosphatemia 335
- 11.5.5 Calcium 336
- 11.5.5.1 Vitamin D 336
- 11.5.5.2 Parathyroid Hormone 337
- 11.5.5.3 Hypocalcemia 337
- 11.5.5.4 Hypercalcemia 337
- 11.5.5.5 Diseases Related to the Parathyroid Hormone 338
- 11.5.5.6 Hyperparathyroidism (HPT) 339
- 11.5.5.7 Osteomalacia 340
- 11.5.5.8 Milk-Alkali Syndrome 340
- 11.5.5.9 Calcifying Disorders 340
- 11.6 Metabolism of Other Trace Elements 341
- 11.6.1 Questionable Essentiality of Nickel, Molybdenum, and Vanadium 341
- 11.6.1.1 Nickel 341
- 11.6.1.2 Molybdenum 342
- 11.6.1.3 Vanadium 342
- 11.6.2 Chromium 343
- 11.6.3 Cobalt and Vitamin B₁₂ 344
- 11.6.4 Manganese 344
- 11.6.5 Selenium 345
- 11.7 Conclusions 346

- 12 Metal Compounds as Enzyme Inhibitors 351**
Gilles Gasser and Nils Metzler-Nolte
- 12.1 Introduction 351
- 12.2 Kinase Inhibitors 352
- 12.3 Proteasome Inhibitors 354
- 12.4 Carbonic Anhydrase Inhibitors (CAIs) 355
- 12.5 Cyclooxygenase Inhibitors 358
- 12.6 Acetylcholinesterase Inhibitors 361
- 12.7 Protein Phosphatase Inhibitors 362
- 12.8 Trypsin and Thrombin Inhibitors 363
- 12.9 Cysteine Protease Inhibitors and Glutathione Transferase Inhibitors 365
- 12.10 HIV-1 Reverse Transcriptase and Protease Inhibitors 368
- 12.11 Telomerase Inhibitors 369
- 12.12 Zinc Finger Protein Inhibitors 372
- 12.13 CXCR4 Inhibitors 372
- 12.14 Xanthine Oxidase Inhibitors 374
- 12.15 Miscellaneous Protein Inhibitors and Conclusions 374

13	Biomedical Applications of Metal-Containing Luminophores	383
	<i>Albert Ruggi, David N. Reinhoudt, and Aldrik H. Velders</i>	
13.1	Introduction: Luminescence in Diagnostics and Imaging	383
13.2	Transition-Metal Containing Luminescent Agents	386
13.2.1	Photophysical Properties of Transition Metal Complexes	386
13.2.2	Ruthenium(II) Complexes	388
13.2.2.1	DNA Binding	388
13.2.2.2	Protein Binding	390
13.2.2.3	Cell Staining	390
13.2.3	Iridium(III) Complexes	391
13.2.4	Rhenium(I) Complexes	392
13.2.5	Platinum(II) Complexes	393
13.2.6	Other Metal Complexes	393
13.3	Lanthanide-Based Luminophores	394
13.3.1	Chemical and Photophysical Properties of Lanthanide Complexes	394
13.3.2	Europium(III) and Terbium(III) Complexes	396
13.3.2.1	Immunoassays	396
13.3.2.2	Nucleic Acid Probes	398
13.3.2.3	Molecular Imaging	398
13.3.3	Neodymium(III) and Ytterbium(III) Complexes	399
13.4	Nanoparticle-Based Luminophores	399
13.4.1	Chemical and Photophysical Properties of Luminescent Nanoparticles	399
13.4.2	Semiconductor Quantum Dots	400
13.4.3	Metal-Doped Nanoparticles	402
13.5	Conclusions and Perspectives	402
	Index	407